Check-Cap (NASDAQ:CHEK) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Check-Cap (NASDAQ:CHEK) in a research report released on Monday. The firm issued a sell rating on the medical research company’s stock.

Check-Cap Trading Down 0.7 %

NASDAQ:CHEK opened at $0.73 on Monday. Check-Cap has a 12 month low of $0.56 and a 12 month high of $3.45. The stock has a market capitalization of $4.27 million, a price-to-earnings ratio of -0.24 and a beta of 0.19. The firm has a fifty day simple moving average of $0.97 and a two-hundred day simple moving average of $1.14.

About Check-Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation.